Nebraska 109th Legislature (2025-2026) Status: Enacted

LB 72 — Change provisions relating to controlled substances schedules under the Uniform Controlled Substances Act

Last action — Approved by Governor on February 25, 2025

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Legislature
  4. ✓
    To Executive
  5. 5
    Enacted

This bill has been enacted into law. Introduced January 09, 2025. Enacted.

Signed by Governor Jim Pillen (Republican) on February 26, 2025.

Prognosis

Likely to advance 70% · moderate confidence

Where this bill stands today.

Odds of enactment

High

How often bills like it became law.

  • Enacted

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

  • Cleared a recorded vote

    Passed 3 recorded votes so far.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Bill Text

What changed in the latest version

1330 added · 1459 removed

Plain-language change summary

The recent amendment to Bill LB 72 updates the definitions and classifications within the Uniform Controlled Substances Act regarding controlled substances in Nebraska. Specifically, it modifies sections about the substances listed under Schedule I, ensuring clarity and consistency in the language used. These changes are important as they help streamline regulations around controlled substances, making it easier for law enforcement and healthcare providers to understand which substances fall under this classification, ultimately aiding in better public health and safety measures.

→
Previous
Latest
LB72 LB72 2025 LEGISLATURE OF NEBRASKA ONE HUNDRED NINTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 72 FINAL READING   Introduced by Hallstrom, 1.
LB72 LB72 2025 LEGISLATIVE BILL 72 Approved by the Governor February 25, 2025   Introduced by Hallstrom, 1.
Read first time January 09, 2025 Committee:
  A BILL FOR AN ACT relating to the Uniform Controlled Substances Act;
Judiciary A BILL FOR AN ACT relating to the Uniform Controlled Substances Act;
Be it enacted by the people of the State of Nebraska, -1- LB72 LB72 2025 Section 1.
Be it enacted by the people of the State of Nebraska, Section 1.
-2- LB72 LB72 2025 (19) Dioxaphetyl butyrate;
(19) Dioxaphetyl butyrate;
(46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N- phenylpropanamide, its optical and geometric isomers, salts, and salts of -3- LB72 LB72 2025 isomers;
(46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N- phenylpropanamide, its optical and geometric isomers, salts, and salts of isomers;
(49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4- piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of isomers;
(49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4- -1- LB72 LB72 2025 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of isomers;
(52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4- piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts of isomers;
(52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N- phenylpropanamide, its optical isomers, salts, and salts of isomers;
(54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4- piperidinyl)-N-phenylpropanamide, its optical and geometric isomers, salts, and salts of isomers;
(54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)- N-phenylpropanamide, its optical and geometric isomers, salts, and salts of isomers;
-4- LB72 LB72 2025 (59) 4-Fluoroisobutyryl Fentanyl;
(59) 4-Fluoroisobutyryl Fentanyl;
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- yl) propionamide;
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) propionamide;
-5- LB72 LB72 2025 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
(88) Ortho-Methyl Methoxyacetyl Fentanyl;
(94) Meta-Fluorofentanyl (N-(3-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)propionamide);
(94) Meta-Fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4- yl)propionamide);
(97) 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylfuran-3-carboxamide);
(97) 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3- carboxamide);
(98) 2',5'-Dimethoxyfentanyl (N-(1-(2,5- dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide);
(98) 2',5'-Dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4- yl)-N-phenylpropionamide);
(101) Alpha-Methylbutyryl fentanyl (2-methyl-N-(1- phenethylpiperidin-4-yl)-N-phenylbutanamide);
(101) Alpha-Methylbutyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4- yl)-N-phenylbutanamide);
(103) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1- yl)-N,N-diethylethan-1-amine);
(103) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)- N,N-diethylethan-1-amine);
(105) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H- benzimidazol-1-yl)ethan-1-amine);
(105) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H- -2- LB72 LB72 2025 benzimidazol-1-yl)ethan-1-amine);
2-(2-(4-ethoxybenzyl)-1H- -6- LB72 LB72 2025 benzimidazol-1-yl)-N,N-diethylethan-1-amine;
2-(2-(4-ethoxybenzyl)-1H- benzimidazol-1-yl)-N,N-diethylethan-1-amine;
(109) 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1- one (commonly known as 2-Methyl AP-237);
(109) 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one (commonly known as 2-Methyl AP-237);
-7- LB72 LB72 2025 (2) Acetyldihydrocodeine;
(2) Acetyldihydrocodeine;
3-(2- dimethylaminoethyl)-5-indolol;
3-(2-dimethylaminoethyl)-5- indolol;
5-hydroxy-N,N- -8- LB72 LB72 2025 dimethyltryptamine;
5-hydroxy-N,N-dimethyltryptamine;
4-bromo-2,5-dimethoxy-alpha- methylphenethylamine;
4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
1-(4-Methoxyphenyl)-N-methylpropan-2- amine, PMMA, and 4-MMA;
1-(4-Methoxyphenyl)-N-methylpropan-2-amine, PMMA, and 4- MMA;
7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9- methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole;
7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole;
Peyote means shall mean all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant or its seeds or extracts;
Peyote means shall mean all parts of the plant presently -3- LB72 LB72 2025 classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant or its seeds or extracts;
(14) Tetrahydrocannabinols, including, but not limited to, synthetic -9- LB72 LB72 2025 equivalents of the substances contained in the plant or in the resinous extractives of cannabis, sp.
(14) Tetrahydrocannabinols, including, but not limited to, synthetic equivalents of the substances contained in the plant or in the resinous extractives of cannabis, sp.
2-thienyl analog of phencyclidine;
2- thienyl analog of phencyclidine;
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo(b,d)pyran;
3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran;
1-(1-phenylcyclohexyl)- pyrrolidine;
1-(1-phenylcyclohexyl)-pyrrolidine;
-10- LB72 LB72 2025 alpha-ET;
alpha-ET;
and/or synthetic substances, derivatives, and their isomers with similar chemical structure and -11- LB72 LB72 2025 pharmacological activity such as the following:
and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as the following:
Any compound containing a 3-(1- naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 1 H-indol-3- yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 1 H-indol-3-yl-(1- naphthyl)methane structure with substitution at the nitrogen atom of the indole -4- LB72 LB72 2025 ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(1- naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a -12- LB72 LB72 2025 naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 2-(3- hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not substituted in or on any of the listed ring systems to any extent;
Any compound containing a 2-(3- hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1- (N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N- methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2- piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Show all 152 changed rows (112 more)
Previous
Latest
-13- LB72 LB72 2025 (I) Adamantoylindoles:
(I) Adamantoylindoles:
Any compound containing a 3-adamantoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3-adamantoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3- tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N- methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 3- tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent;
Any compound containing a 1-indole-3- carboxamide structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxamide group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;
Any compound containing a 1-indole-3-carboxamide structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxamide group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1- mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;
Any compound containing a 1-indole-3- carboxylate structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, -14- LB72 LB72 2025 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxylate group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;
Any compound containing a 1-indole-3-carboxylate structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, substitution at the carboxylate group by an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to the adamantyl, 1- mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent;
(29) (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2- phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation;
(29) (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1- yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts, and -5- LB72 LB72 2025 salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation;
-15- LB72 LB72 2025 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups;
(A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups;
(i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
(i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known as 2C- C or 2,5-Dimethoxy-4-chlorophenethylamine;
-16- LB72 LB72 2025 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
(xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
25B- NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
25B-NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
25I- NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
25I-NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
or 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
or 25C- NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
(xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2- b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY- NBOMe;
(xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-b:4,5- b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-NBOMe;
(xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, which is also known as bromo-benzodifuranylisopropylamine or bromo- dragonFLY;
(xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, which is also known as bromo-benzodifuranylisopropylamine or bromo-dragonFLY;
(xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known -17- LB72 LB72 2025 as 5-APDB;
(xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known as 5- APDB;
(xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5- dimethoxy-a-methylphenethylamine;
(xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-dimethoxy-a- methylphenethylamine;
(xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as 4-methyl-2,5-dimethoxy-amethylphenethylamine;
(xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as 4- -6- LB72 LB72 2025 methyl-2,5-dimethoxy-amethylphenethylamine;
(xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
(xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known as N- ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
(A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO- DALT;
(A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-DALT;
-18- LB72 LB72 2025 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO- DMT or OAcetylpsilocin;
(B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-DMT or OAcetylpsilocin;
(C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4- HO-MET;
(C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-HO-MET;
(D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4- HO-DIPT;
(D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-HO-DIPT;
(E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as 5-MeOMiPT;
(E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as 5- MeOMiPT;
(F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO- DMT;
(F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-DMT;
(G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5- MeO-DiPT;
(G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-MeO- DiPT;
or (B) Unless listed in another schedule, any substance which contains any quantity of any material, compound, mixture, or structure, other than bupropion, that is structurally derived by any means from 2- aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:
or (B) Unless listed in another schedule, any substance which contains any quantity of any material, compound, mixture, or structure, other than bupropion, that is structurally derived by any means from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:
-19- LB72 LB72 2025 (i) Substitution in the ring system to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(i) Substitution in the ring system to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
or 4,5- -20- LB72 LB72 2025 dihydro-5-phenyl-2-oxazolamine;
or 4,5-dihydro-5- phenyl-2-oxazolamine;
alpha- aminopropiophenone;
alpha-aminopropiophenone;
2-aminopropiophenone;
2- aminopropiophenone;
alpha- N-methylaminopropiophenone;
alpha-N- methylaminopropiophenone;
N-methylcathinone;
N- methylcathinone;
and (+/-)cis-4,5-dihydro-4-methyl-5- phenyl-2-oxazolamine;
and (+/-)cis-4,5-dihydro-4-methyl-5- -7- LB72 LB72 2025 phenyl-2-oxazolamine;
and (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5-yl)carbamimidate), including its salts, isomers, and salts of isomers;
and (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5- yl)carbamimidate), including its salts, isomers, and salts of isomers;
(11) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3- oxadiazol-3-ium-5-yl)carbamimidate);
(11) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5-yl)carbamimidate);
(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, buprenorphine, -21- LB72 LB72 2025 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone and their salts, but including the following:
(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, buprenorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone and their salts, but including the following:
(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent to or identical with any of these substances, including cocaine or ecgonine and its salts, optical isomers, and salts of optical isomers, except that the substances shall not include decocainized coca leaves or extractions which do not contain -22- LB72 LB72 2025 cocaine or ecgonine;
(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent to or identical with any of these substances, including cocaine or ecgonine and its salts, optical isomers, and salts of optical isomers, except that the substances shall not include decocainized coca leaves or extractions which do not contain cocaine or ecgonine;
(12) Moramide-intermediate, 2-methyl-3-morpholino-1,1- diphenylpropane-carboxylic acid;
(12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane- carboxylic acid;
(17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4- carboxylate;
(17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4- carboxylic acid;
(18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
-23- LB72 LB72 2025 (19) Phenazocine;
(19) Phenazocine;
(23) Dihydrocodeine;
-8- LB72 LB72 2025 (23) Dihydrocodeine;
-24- LB72 LB72 2025 (3) Pentobarbital;
(3) Pentobarbital;
Phenyl-2-propanone;
Phenyl-2- propanone;
-25- LB72 LB72 2025 (3) Clortermine;
(3) Clortermine;
(22) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt thereof and one or more other -26- LB72 LB72 2025 active medicinal ingredients which are not listed in any schedule;
-9- LB72 LB72 2025 (22) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule;
(+/-)-2-(2-chlorophenyl)-2-(methylamino)- cyclohexanone;
(+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
2-(ethylamino)-2-(2-thienyl)- cyclohexanone.
2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
4-(2-fluorophenyl)-6,8-dihydro-1,3,8- trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon;
4-(2- fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)- one, and flupyrazapon;
-27- LB72 LB72 2025 (viii) Xylazine-M (HO-) isomer 1 glucuronide;
(viii) Xylazine-M (HO-) isomer 1 glucuronide;
(iv) The manufacturing, distribution, or use of a xylazine bulk chemical for pharmaceutical compounding by licensed pharmacists or veterinarians for a nonhuman species in accordance with subdivision (B) (i) or (ii) of this subdivision (27);
(iv) The manufacturing, distribution, or use of a xylazine bulk chemical for pharmaceutical compounding by licensed pharmacists or veterinarians for a nonhuman species in accordance with subdivision (B)(i) or (ii) of this subdivision (27);
or (v) Any other use approved or permissible under the Federal Food, -28- LB72 LB72 2025 Drug, and Cosmetic Act, when dispensed or prescribed for, or administered to, a nonhuman species in accordance with subdivision (B)(i) or (ii) of this subdivision (27).
or (v) Any other use approved or permissible under the Federal Food, Drug, and Cosmetic Act, when dispensed or prescribed for, or administered to, a nonhuman species in accordance with subdivision (B)(i) or (ii) of this subdivision (27).
and (F) Not more than fifty milligrams of morphine per one hundred milliliters or per one hundred grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
and (F) Not more than fifty milligrams of morphine per one hundred milliliters -10- LB72 LB72 2025 or per one hundred grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
and -29- LB72 LB72 2025 (2) Any material, compound, mixture, or preparation containing any of the following narcotic drug or its salts, as set forth below:
and (2) Any material, compound, mixture, or preparation containing any of the following narcotic drug or its salts, as set forth below:
(4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1- ene);
(4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-ene);
(5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1- ene);
(5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-ene);
(11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta- hydroxyandrost-4-en-3-one);
(11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3- one);
(14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4- en-3-one);
(14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3- one);
(16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17- alpha-methyl-androst-1,4-dien-3-one);
(16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-alpha- methyl-androst-1,4-dien-3-one);
-30- LB72 LB72 2025 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2- en-17-beta-ol) (a.k.a.
(17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-en-17- beta-ol) (a.k.a.
(20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha- androstan-3-one);
(20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3- one);
(2-formyl-17-alpha-methyl-11- alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
(2-formyl-17-alpha-methyl-11-alpha,17- beta-dihydroxyandrost-1,4-dien-3-one);
(24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]- furazan);
(24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-furazan);
(27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3- one);
(27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-one);
(28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3- one);
(28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one);
(29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3- one);
(29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one);
(30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4- dien-3-one);
(30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-dien-3- one);
(31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5- ene);
(31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-ene);
(32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17- beta-ol-3-one);
(32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-beta- ol-3-one);
(33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3- one);
(33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-one);
-31- LB72 LB72 2025 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
(35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
(37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4- hydroxy-17-beta-hydroxyestr-4-en-3-one);
(37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-hydroxy-17- beta-hydroxyestr-4-en-3-one);
(38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)- dien-3-one);
(38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-dien-3- one);
(40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4- en-3-one);
(40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-en-3- one);
(41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4- en-3-one);
(41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-en-3- one);
(42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta- hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a.
(42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-hydroxy-17- alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a.
'17-alpha- methyl-1-testosterone');
'17-alpha-methyl-1- testosterone');
(48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17- dione);
(48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
(51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4- en-3-one);
(51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-en-3- one);
(53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3- one);
(53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-one);
(54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3- one);
-11- LB72 LB72 2025 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-one);
-32- LB72 LB72 2025 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]- androstan-3-one);
(55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]- androstan-3-one);
(56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4- en-3-one);
(56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-en-3-one);
(57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta- hydroxy-[5-alpha]-androstan-3-one);
(57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-hydroxy-[5- alpha]-androstan-3-one);
(58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2- c]pyrazole);
(58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-c]pyrazole);
(59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]- androst-2-eno[3,2-c]-pyrazole);
(59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-androst-2- eno[3,2-c]-pyrazole);
(60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3- one);
(60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-one);
(61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17- oic acid lactone);
(61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
(73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17 beta-ol;
(73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17 beta- ol;
(75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11- dione;
(75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-dione;
-33- LB72 LB72 2025 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
(76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
Some other names for dronabinol are (6aR- trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
Some other names for dronabinol are (6aR-trans)-6a,7,8,10a- tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)pyran-1-ol or (-)-delta-9- (trans)-tetrahydrocannabinol.
-34- LB72 LB72 2025 (7) Daridorexant;
(7) Daridorexant;
(32) Halazepam;
-12- LB72 LB72 2025 (32) Halazepam;
-35- LB72 LB72 2025 (38) Medazepam;
(38) Medazepam;
(b) Any material, compound, mixture, or preparation which contains any quantity of the following substance, including its salts, isomers, whether optical, position, or geometric, and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is -36- LB72 LB72 2025 possible:
(b) Any material, compound, mixture, or preparation which contains any quantity of the following substance, including its salts, isomers, whether optical, position, or geometric, and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
and (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers, and salts of these isomers to -37- LB72 LB72 2025 include:
and (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers, and salts of these isomers to include:
(2) The following drug products containing ephedrine, its salts, optical isomers, and salts of such optical isomers, are excepted from subdivision (f)(1) (g)(1) of Schedule IV if they (A) are stored behind a counter, in an area not accessible to customers, or in a locked case so that a customer needs assistance from an employee to access the drug product;
(2) The following drug products containing ephedrine, its salts, optical isomers, and salts of such optical isomers, are excepted from subdivision (f) (1) (g)(1) of Schedule IV if they (A) are stored behind a counter, in an area not accessible to customers, or in a locked case so that a customer needs -13- LB72 LB72 2025 assistance from an employee to access the drug product;
(C) are labeled and marketed in a manner consistent with the pertinent OTC Tentative Final or Final -38- LB72 LB72 2025 Monograph;
(C) are labeled and marketed in a manner consistent with the pertinent OTC Tentative Final or Final Monograph;
(b) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which -39- LB72 LB72 2025 contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(b) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
28-416 (1) Except as authorized by the Uniform Controlled Substances Act, it shall be unlawful for any person knowingly or intentionally:
28-416 (1) Except as authorized by the Uniform Controlled Substances Act, it shall be unlawful for any person knowingly or intentionally:
(b) any other -40- LB72 LB72 2025 controlled substance classified in Schedule I, II, or III of section 28-405 shall be guilty of a Class IIA felony;
(b) any other controlled substance classified in Schedule I, II, or III of section 28-405 shall be guilty of a Class IIA felony;
(4)(a) Except as authorized by the Uniform Controlled Substances Act, any person eighteen years of age or older who knowingly or intentionally manufactures, distributes, delivers, dispenses, or possesses with intent to manufacture, distribute, deliver, or dispense a controlled substance or a counterfeit controlled substance (i) to a person under the age of eighteen years, (ii) in, on, or within one thousand feet of the real property comprising a public or private elementary, vocational, or secondary school, a community college, a public or private college, junior college, or university, or a playground, or (iii) within one hundred feet of a public or private youth center, public swimming pool, or video arcade facility shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10) of this section, depending upon the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher penalty classification than that prescribed for a first violation of this subsection, but in no event shall such person be punished by a penalty -41- LB72 LB72 2025 greater than a Class IB felony.
(4)(a) Except as authorized by the Uniform Controlled Substances Act, any -14- LB72 LB72 2025 person eighteen years of age or older who knowingly or intentionally manufactures, distributes, delivers, dispenses, or possesses with intent to manufacture, distribute, deliver, or dispense a controlled substance or a counterfeit controlled substance (i) to a person under the age of eighteen years, (ii) in, on, or within one thousand feet of the real property comprising a public or private elementary, vocational, or secondary school, a community college, a public or private college, junior college, or university, or a playground, or (iii) within one hundred feet of a public or private youth center, public swimming pool, or video arcade facility shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10) of this section, depending upon the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher penalty classification than that prescribed for a first violation of this subsection, but in no event shall such person be punished by a penalty greater than a Class IB felony.
(c) Any person who violates subdivision (a) or (b) of this -42- LB72 LB72 2025 subsection shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10) of this section, depending upon the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher penalty classification than that prescribed for a first violation of this subsection, but in no event shall such person be punished by a penalty greater than a Class IB felony.
(c) Any person who violates subdivision (a) or (b) of this subsection shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10) of this section, depending upon the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher penalty classification than that prescribed for a first violation of this subsection, but in no event shall such person be punished by a penalty greater than a Class IB felony.
-43- LB72 LB72 2025 (a) One hundred forty grams or more shall be guilty of a Class IB felony;
(a) One hundred forty grams or more shall be guilty of a Class IB felony;
(b) At least twenty-eight grams but less than one hundred forty grams shall be guilty of a Class IC felony;
-15- LB72 LB72 2025 (b) At least twenty-eight grams but less than one hundred forty grams shall be guilty of a Class IC felony;
(13) Except as provided in section 28-1701, any person knowingly or intentionally possessing marijuana weighing one ounce or less or any substance containing a quantifiable amount of the substances, chemicals, or compounds described, defined, or delineated in subdivision (c)(28) (c) (27) of Schedule I of section 28-405 shall:
(13) Except as provided in section 28-1701, any person knowingly or intentionally possessing marijuana weighing one ounce or less or any substance containing a quantifiable amount of the substances, chemicals, or compounds described, defined, or delineated in subdivision (c)(28) (c)(27) of Schedule I of section 28-405 shall:
-44- LB72 LB72 2025 (b) For the second offense, be guilty of a Class IV misdemeanor, receive a citation, and be fined four hundred dollars and may be imprisoned not to exceed five days;
(b) For the second offense, be guilty of a Class IV misdemeanor, receive a citation, and be fined four hundred dollars and may be imprisoned not to exceed five days;
(18) In addition to the existing penalties available for a violation of subsection (1) of this section, including any criminal attempt or conspiracy to violate subsection (1) of this section, a sentencing court may order that any money, securities, negotiable instruments, firearms, conveyances, or electronic communication devices as defined in section 28-833 or any equipment, components, peripherals, software, hardware, or accessories related to electronic communication devices be forfeited as a part of the sentence imposed if it finds by clear and convincing evidence -45- LB72 LB72 2025 adduced at a separate hearing in the same prosecution, following conviction for a violation of subsection (1) of this section, and conducted pursuant to section 28-1601, that any or all such property was derived from, used, or intended to be used to facilitate a violation of subsection (1) of this section.
(18) In addition to the existing penalties available for a violation of subsection (1) of this section, including any criminal attempt or conspiracy to violate subsection (1) of this section, a sentencing court may order that any money, securities, negotiable instruments, firearms, conveyances, or electronic communication devices as defined in section 28-833 or any equipment, components, peripherals, software, hardware, or accessories related to electronic communication devices be forfeited as a part of the sentence imposed if it finds by clear and convincing evidence adduced at a separate hearing in the same prosecution, following conviction for a violation of subsection (1) of this section, and conducted pursuant to section 28-1601, that any or all such property was derived from, used, or intended to be used to facilitate a violation of subsection (1) of this section.
(i) For the first offense, the court may, as part of the judgment of conviction or adjudication, (A) prohibit such person from obtaining any permit or any license pursuant to the act for which such person would otherwise be eligible until thirty days after the date of such order and -46- LB72 LB72 2025 (B) require such person to attend a drug education class;
(i) For the first offense, the court may, as part of the judgment of conviction or adjudication, (A) prohibit such person from obtaining any permit or any license pursuant to the act for which such person would otherwise be eligible until thirty days after the date of such order and (B) require such person to attend a drug education class;
and (iii) For a third or subsequent offense, the court may, as part of the judgment of conviction or adjudication, (A) prohibit such person from obtaining any permit or any license pursuant to the act for which such person would otherwise be eligible until twelve months after the date of such order and (B) require such person to complete no fewer than sixty hours of community service, to attend a drug education class, and to submit to a drug assessment by a licensed alcohol and drug counselor.
and (iii) For a third or subsequent offense, the court may, as part of the -16- LB72 LB72 2025 judgment of conviction or adjudication, (A) prohibit such person from obtaining any permit or any license pursuant to the act for which such person would otherwise be eligible until twelve months after the date of such order and (B) require such person to complete no fewer than sixty hours of community service, to attend a drug education class, and to submit to a drug assessment by a licensed alcohol and drug counselor.
-47-
-17-
⬇ Download PDF
View plain text versions (3)

Action History

  1. Approved by Governor on February 25, 2025

  2. Dispensing of reading at large approved

  3. Passed on Final Reading 47-1*-1

  4. President/Speaker signed

  5. Presented to Governor on February 21, 2025

  6. Placed on Final Reading

  7. Advanced to Enrollment and Review for Engrossment

  8. Placed on Select File

  9. Advanced to Enrollment and Review Initial

  10. Placed on General File

  11. Notice of hearing for January 22, 2025

  12. Referred to Judiciary Committee

  13. Date of introduction

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 48 not signed on · 2 voted No

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (48)

48 members have not signed on to this bill.

Show all 48 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Passed on Final Reading 47-1*-1

Passed 47 Yea · 1 Nay · 1 Other
Party YeaNayPresentNot Voting
Unaffiliated 47101
Total 47101
% of votes cast 96%2%0%2%
How each member voted (49)
Member Party Vote
McKeon — Yea
Meyer — Yea
Ashlei Spivey — Yea
Barry DeKay — Yea
Beau Ballard — Yea
Ben Hansen — Yea
Bob Andersen — Yea
Bob Hallstrom — Yea
Brian Hardin — Yea
Carolyn Bosn — Yea
Christy Armendariz — Yea
Dan Lonowski — Yea
Dan Quick — Yea
Danielle Conrad — Yea
Dave Murman — Yea
Dave Wordekemper — Yea
Dunixi Guereca — Yea
Eliot Bostar — Yea
George Dungan — Yea
Jana Hughes — Yea
Jane Raybould — Yea
Jared Storm — Yea
Jason Prokop — Yea
John Arch — Yea
John Cavanaugh — Yea
John Fredrickson — Yea
Kathleen Kauth — Yea
Loren Lippincott — Yea
Machaela Cavanaugh — Yea
Margo Juarez — Yea
Megan Hunt — Nay
Merv Riepe — Yea
Mike Jacobson — Yea
Mike Moser — Yea
Myron Dorn — Yea
Paul Strommen — Yea
R. Brad von Gillern — Yea
Rick Holdcroft — Yea
Rita Sanders — Yea
Robert Clements — Yea
Robert Dover — Yea
Stan Clouse — Yea
Tanya Storer — Yea
Teresa Ibach — Yea
Terrell McKinney — Not Voting
Tom Brandt — Yea
Tony Sorrentino — Yea
Victor Rountree — Yea
Wendy DeBoer — Yea

Official roll call →

Advanced to Enrollment and Review for Engrossment

Passed 32 Yea · 1 Nay · 16 Other
Party YeaNayPresentNot Voting
Unaffiliated 321016
Total 321016
% of votes cast 65%2%0%33%
How each member voted (49)
Member Party Vote
McKeon — Yea
Meyer — Yea
Ashlei Spivey — Not Voting
Barry DeKay — Yea
Beau Ballard — Yea
Ben Hansen — Not Voting
Bob Andersen — Yea
Bob Hallstrom — Yea
Brian Hardin — Yea
Carolyn Bosn — Not Voting
Christy Armendariz — Yea
Dan Lonowski — Not Voting
Dan Quick — Yea
Danielle Conrad — Not Voting
Dave Murman — Yea
Dave Wordekemper — Not Voting
Dunixi Guereca — Yea
Eliot Bostar — Not Voting
George Dungan — Not Voting
Jana Hughes — Yea
Jane Raybould — Yea
Jared Storm — Yea
Jason Prokop — Yea
John Arch — Yea
John Cavanaugh — Not Voting
John Fredrickson — Not Voting
Kathleen Kauth — Yea
Loren Lippincott — Yea
Machaela Cavanaugh — Not Voting
Margo Juarez — Not Voting
Megan Hunt — Not Voting
Merv Riepe — Not Voting
Mike Jacobson — Yea
Mike Moser — Yea
Myron Dorn — Yea
Paul Strommen — Yea
R. Brad von Gillern — Yea
Rick Holdcroft — Yea
Rita Sanders — Yea
Robert Clements — Yea
Robert Dover — Not Voting
Stan Clouse — Yea
Tanya Storer — Yea
Teresa Ibach — Yea
Terrell McKinney — Nay
Tom Brandt — Yea
Tony Sorrentino — Yea
Victor Rountree — Not Voting
Wendy DeBoer — Yea

Official roll call →

Advanced to Enrollment and Review Initial

Passed 39 Yea · 0 Nay · 10 Other
Party YeaNayPresentNot Voting
Unaffiliated 390010
Total 390010
% of votes cast 80%0%0%20%
How each member voted (49)
Member Party Vote
McKeon — Yea
Meyer — Yea
Ashlei Spivey — Not Voting
Barry DeKay — Yea
Beau Ballard — Yea
Ben Hansen — Yea
Bob Andersen — Yea
Bob Hallstrom — Not Voting
Brian Hardin — Yea
Carolyn Bosn — Yea
Christy Armendariz — Yea
Dan Lonowski — Yea
Dan Quick — Yea
Danielle Conrad — Not Voting
Dave Murman — Yea
Dave Wordekemper — Yea
Dunixi Guereca — Yea
Eliot Bostar — Not Voting
George Dungan — Yea
Jana Hughes — Yea
Jane Raybould — Not Voting
Jared Storm — Yea
Jason Prokop — Yea
John Arch — Yea
John Cavanaugh — Not Voting
John Fredrickson — Yea
Kathleen Kauth — Yea
Loren Lippincott — Yea
Machaela Cavanaugh — Yea
Margo Juarez — Yea
Megan Hunt — Not Voting
Merv Riepe — Yea
Mike Jacobson — Yea
Mike Moser — Yea
Myron Dorn — Yea
Paul Strommen — Not Voting
R. Brad von Gillern — Yea
Rick Holdcroft — Yea
Rita Sanders — Yea
Robert Clements — Yea
Robert Dover — Not Voting
Stan Clouse — Yea
Tanya Storer — Yea
Teresa Ibach — Yea
Terrell McKinney — Not Voting
Tom Brandt — Yea
Tony Sorrentino — Yea
Victor Rountree — Yea
Wendy DeBoer — Yea

Official roll call →

Subjects

public-safety health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors LB 72?
LB 72 is sponsored by Bob Hallstrom.
What is the current status of LB 72?
This bill has been enacted into law. Introduced January 09, 2025. Enacted.
Where can I track LB 72?
Track LB 72 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on LB 72

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of LB 72

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →